Get AUVI-Q for $0 out-of-pocket

Eligibility details

The first and only FDA-approved
epinephrine auto-injector
for infants and toddlers
weighing 16.5 lbs to 33 lbs
with life-threatening

Only AUVI-q® (epinephrine injection, USP) has features specifically designed for infants and toddlers weighing 16.5 lbs to 33 lbs.


Smallest dose delivered by an
epinephrine auto-injector
Each AUVI-q contains a single 0.1 mg
epinephrine dose.


Shortest needle length The shortest available needle among
epinephrine auto-injectors that helps
deliver the dose at the right depth.

product group Ready to prescribe?

Questions or concerns about your patient’s insurance coverage of AUVI-q?

Get your questions answered.

Call 1-877-30-AUVIQ

The most innovative epinephrine auto-injector on the market. Designed to be easy to use.

The AUVI-Q product family was designed to be easy to use, and to help maximize the safe administration of epinephrine and minimize the potential for use-related errors during injection.


AUVI-Q is about the size of a credit card and thickness of a cell phone, and fits into most pockets, small purses, and diaper bags.

audio icon

AUVI-Q includes innovative features such as voice instructions.

opposing arrows

AUVI-Q is the first-and-only epinephrine auto-injector with an auto-retractable needle. Patients may not feel an injection when it occurs.

Obtain AUVI-Q for your commercially insured patients for $0 out-of-pocket* through the direct delivery service.

*Please see full terms and conditions. Learn more


AUVI-Q® (epinephrine injection, USP) is indicated in the emergency treatment of allergic reactions (Type I) including anaphylaxis to allergens, idiopathic and exercise-induced anaphylaxis. AUVI-Q is intended for patients with a history of anaphylactic reactions or who are at increased risk for anaphylaxis.

Important Safety Information

AUVI-Q is intended for immediate self-administration as emergency supportive therapy only and is not a substitute for immediate medical care. In conjunction with the administration of epinephrine, the patient should seek immediate medical or hospital care. Each AUVI-Q contains a single dose of epinephrine for single-use injection. More than two sequential doses of epinephrine should only be administered under direct medical supervision. Since the doses of epinephrine delivered from AUVI-Q are fixed, consider using other forms of injectable epinephrine if doses lower than 0.1 mg are deemed necessary.

AUVI-Q should ONLY be injected into the anterolateral aspect of the thigh. Do not inject intravenously, or into buttock, digits, hands, or feet. Instruct caregivers to hold the leg of young children and infants firmly in place and limit movement prior to and during injection to minimize the risk of injection-related injury.

Rare cases of serious skin and soft tissue infections have been reported following epinephrine injection. Advise patients to seek medical care if they develop any of the following symptoms at an injection site: redness that does not go away, swelling, tenderness, or the area feels warm to the touch.

Epinephrine should be administered with caution to patients with certain heart diseases, and in patients who are on medications that may sensitize the heart to arrhythmias, because it may precipitate or aggravate angina pectoris and produce ventricular arrhythmias. Arrhythmias, including fatal ventricular fibrillation, have been reported in patients with underlying cardiac disease or taking cardiac glycosides or diuretics. Patients with certain medical conditions or who take certain medications for allergies, depression, thyroid disorders, diabetes, and hypertension, may be at greater risk for adverse reactions. Common adverse reactions to epinephrine include anxiety, apprehensiveness, restlessness, tremor, weakness, dizziness, sweating, palpitations, pallor, nausea and vomiting, headache, and/or respiratory difficulties.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.